Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy

Cardiology in Review

Volumn 10, Issue 3, 2002, Pages 173-181

  Maron, Barry J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

Hypertrophic cardiomyopathy; Implantable defibrillator; Sudden death

Indexed keywords

CARDIOVERSION; DEFIBRILLATOR; HEART DEATH; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; REVIEW; RISK ASSESSMENT; SUDDEN DEATH;

EID: 0036300982     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200205000-00006     Document Type: Review

References (42)

1. Hypertrophic cardiomyopathy
2. Hypertrophic cardiomyopathy: Clinical spectrum and treatment
3. The management of hypertrophic cardiomyopathy
4. Asymmetrical hypertrophy of the heart in young patients
5. Hypertrophic cardiomyopathy: An important cause of sudden death
6. Sudden death in hypertrophic cardiomyopathy: Profile of 78 patients
7. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral based patient population
8. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia
9. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy
10. Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study
11. Sudden death in hypertrophic cardiomyopathy: Assessment of patients at high risk
12. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy
13. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
14. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy
15. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history
16. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia
17. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population
18. Hypertrophic cardiomyopathy: Interrelation of clinical manifestations, pathophysiology, and therapy (part I)
19. Hypertrophic cardiomyopathy: Interrelation of clinical manifestations, pathophysiology, and therapy (part II)
20. Hypertrophic cardiomyopathy and sudden death
21. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy
22. Patterns and prognostic significance of ventricular ectopy in an unselected and unreferred patient population with hypertrophic cardiomyopathy
23. Survival after cardiac arrest in patients with hypertrophic cardiomyopathy
24. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy
25. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy
26. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy
27. Sudden death in young competitive athletes: Clinical, demographic and pathological profiles
28. Clinical consequences of hypertrophic cardiomyopathy in an unselected regional United States cohort
29. Prognostic determinants in hypertrophic cardiomyopathy: Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic and electrophysiologic findings
30. Prospective diagnostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy
31. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings
32. A comparison of anitarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
33. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
34. Internal ventricular defibrillation
35. Arrhythmogenic right ventricular dysplasia: Clinical results with implantable cardioverter defibrillator
36. Hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator
37. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients
38. Extreme left ventricular hypertrophy
39. Survival after cardiac arrest in patients with hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator
40. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest
41. Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA Study
42. "Malignant" hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature deaths